Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of intravenous ABCB5+ mesenchymal stromal cells for epidermolysis bullosa
NL-OMON58708Phase 3Completed
- Sponsor
- RHEACELL
- Start
- Jan 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of EBESANAR in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and junctional epidermolysis bullosa (JEB) (3 arms), sponsored by RHEACELL. Primary endpoint: Complete target wound closure at Month 6 in RDEB age 1 year or older. Started Jan 2023; status: completed.
02
Drugs
EBESANAR
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)junctional epidermolysis bullosa (JEB)
Beyond the preview
Go deeper on NL-OMON58708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58708.